Next Article in Journal
High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India
Next Article in Special Issue
Review of the Novel Investigational Antifungal Olorofim
Previous Article in Journal
Antifungal Activity of Antimicrobial Peptides and Proteins against Aspergillus fumigatus
Open AccessReview

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, A-6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
J. Fungi 2020, 6(2), 66; https://doi.org/10.3390/jof6020066
Received: 27 April 2020 / Revised: 14 May 2020 / Accepted: 15 May 2020 / Published: 18 May 2020
(This article belongs to the Special Issue Antifungal Agents Recently Approved or Under Development)
As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds. However, the main drawback of the present formulations remains its toxicity, the limited use to intravenous administration, and the higher costs associated with the better tolerated lipid formulations. The novel nanoparticle-based encochleated AmB (CAmB) formulation encapsulates, protects, and delivers its cargo molecule AmB in the interior of a calcium-phospholipid anhydrous crystal. Protecting AmB from harsh environmental conditions and gastrointestinal degradation, CAmB offers oral availability in conjunction with reduced toxicity. Matinas BioPharma, Bedminster, NJ is on the way to develop CAmB named MAT2203, currently undergoing Phase II clinical trials. View Full-Text
Keywords: amphotericin B; oral availability; antifungals; cochleates; MAT2203 amphotericin B; oral availability; antifungals; cochleates; MAT2203
MDPI and ACS Style

Aigner, M.; Lass-Flörl, C. Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached? J. Fungi 2020, 6, 66.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop